SEC Form 4 · accession 0001140361-17-005058
NEVRO CORP · NVRO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Michael Enxing
Officer — VP of Sales
Period of report
Feb 6, 2017
Accepted (ET)
Feb 8, 2017 · 12:52 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001444380
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Feb 6, 2017 | M | 1,500 | $3.60 | A | 78,963 | D | |
| Common StockF3,F1 | Feb 6, 2017 | S | 1,500 | $93.2722 | D | 77,463 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F4 | $3.60 | Feb 6, 2017 | M | 1,500 | D | — | Dec 17, 2022 | Common Stock | 1,500 | 40,108 | D |
Explanation of responses
- F1Includes 2,500 restricted stock units.
- F2The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan.
- F3The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $92.86 to $93.64, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- F4100% of the shares subject to the option are fully vested and exercisable.